Cargando…

1974. Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis

BACKGROUND: Ceftriaxone–sulbactam–disodium EDTA (CSE) is being developed for Gram-negative infections caused by multidrug-resistant (MDR) bacteria. PLEA was a Phase 3, double-blind, multicenter, randomized study of CSE vs. meropenem (MR) for treatment of adults with complicated urinary tract infecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandale, Pankaj, Mir, Mohd Amin, Chaudhary, Saransh, Chaudhary, Manu, Sood, Rajeev, Patil, N S, Narang, Salil, Pyasi, Anurag, Shameem, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253172/ http://dx.doi.org/10.1093/ofid/ofy210.1630

Ejemplares similares

1984. Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of Failed Patients With Assessment of MIC Increases and Changes in Genotypic Profile in PLEA (a Phase 3, Randomized, Double-Blind Clinical Trial in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis)
por: Mir, Mohd Amin, et al.
Publicado: (2018)

Ceftriaxone+Sulbactam+Disodium EDTA Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial
por: Mir, Mohd Amin, et al.
Publicado: (2019)

1373. Activity of Ceftriaxone–Sulbactam–EDTA Against Multi-Drug-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India
por: Girotra, Ruchi, et al.
Publicado: (2018)

1959. Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-Blind Trial): Outcomes in Patients Infected With Ceftriaxone Non-Susceptible, Extended-Spectrum β-Lactamase and Multi-Drug-resistant Pathogens at Baseline
por: Mir, Mohd Amin, et al.
Publicado: (2018)

A Novel High Performance Liquid Chromatographic Method for Simultaneous Determination of Ceftriaxone and Sulbactam in Sulbactomax
por: Shrivastava, Sanjay Mohan, et al.
Publicado: (2009)

Protective role of ceftriaxone plus sulbactam with VRP1034 on oxidative stress, hematological and enzymatic parameters in cadmium toxicity induced rat model
por: Dwivedi, Vivek Kumar, et al.
Publicado: (2012)

381. Effect of Ceftriaxone+sulbactam+disodium EDTA Combination in Treatment of Complicated Urinary Tract Infections Caused by Metallo Beta-lactamase Producing Enterobacterales: An Open Label Randomized Controlled Trial
por: Samantaray, Subhashree, et al.
Publicado: (2023)

Safety and efficacy of a novel drug elores (ceftriaxone + sulbactam + disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study
por: Chaudhary, Manu, et al.
Publicado: (2017)

Comparison of different ratios of cefoperazone/sulbactam in patients with pyelonephritis
por: Jiang, Weizhong, et al.
Publicado: (2023)

A Comparative In Vitro Sensitivity Study of “Ceftriaxone–Sulbactam–EDTA” and Various Antibiotics against Gram-negative Bacterial Isolates from Intensive Care Unit
por: Singh, Sweta, et al.
Publicado: (2020)

A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections
por: Xin, Xiaojuan, et al.
Publicado: (2013)

An In Vitro Susceptibility Study of Cefotaxime-Sulbactam on Clinical Bacterial Isolates From Various Regions in India: A Comparison With Ceftriaxone-Sulbactam
por: Gondane, Ajitkumar A, et al.
Publicado: (2023)

Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats
por: Roy, Dilip, et al.
Publicado: (2021)

Correlation Between Cefoperazone/Sulbactam MIC Values and Clinical Outcomes of Escherichia coli Bacteremia
por: Lin, Shang-Yi, et al.
Publicado: (2022)

1220. Is MIC all that matters? MIC Distributions of Ceftazidime and Cefepime in Ceftriaxone-Resistant E. coli and Klebsiella spp
por: Heil, Emily, et al.
Publicado: (2021)

Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa
por: Nussbaumer-Pröll, A., et al.
Publicado: (2022)

C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem
por: Zhao, Yichang, et al.
Publicado: (2022)

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane(®)): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects
por: Saxena, Sumit, et al.
Publicado: (2022)

In Vitro Susceptibility of Clinical Isolates to Ceftriaxone Alone and Ceftriaxone in Combination With Sulbactam or Tazobactam: A Comparative Study of Broad-Spectrum β-Lactam Antibiotics in India
por: Sanghavi, Sonali, et al.
Publicado: (2023)

Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii
por: Zhu, Shixing, et al.
Publicado: (2022)

2131. Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for Enterobacteriaceae Using MicroScan Dried Gram-Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2019)

Evaluation of ceftriaxone-sulbactam-disodium edetate adjuvant combination against multi-drug resistant Gram-negative organisms
por: Gupta, Shilpi, et al.
Publicado: (2020)

Clinical Outcomes Of Colistin In Combination With Either 6-G Sulbactam Or Carbapenems For The Treatment Of Extensively Drug-Resistant Acinetobacter Baumannii Pneumonia With High MIC To Sulbactam, A Prospective Cohort Study
por: Ungthammakhun, Chutchawan, et al.
Publicado: (2019)

Genomic Background and Phylogeny of cfiA-Positive Bacteroides fragilis Strains Resistant to Meropenem-EDTA
por: Valdezate, Sylvia, et al.
Publicado: (2021)

Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the β-Lactamase Inhibitor LN-1-255 against Acinetobacter spp.
por: Lasarte-Monterrubio, Cristina, et al.
Publicado: (2021)

2138. In Vitro Susceptibility of Recent Clinical Isolates of P. aeruginosa and Enterobacterales to Imipenem or Meropenem Alone or in Combination with Sulbactam-Durlobactam
por: McLeod, Sarah, et al.
Publicado: (2023)

Comparison between Ceftriaxone and Sulbactam-Ampicillin as Initial Treatment of Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis
por: Kato, Hideo, et al.
Publicado: (2022)

656. Sulbactam-Durlobactam MIC Determination: Comparative Evaluation of the New ETEST(®) SUD to the CLSI 2021 Broth Microdilution Method
por: Sauvonnet, Veronique, et al.
Publicado: (2021)

CSE-1034 versus Ceftriaxone: Efficacy and Safety Analysis from a Randomized, Open-labeled Phase III Study in Complicated Urinary Tract Infections
por: Chaudhary, Manu, et al.
Publicado: (2018)

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii
por: Zhang, Jiayuan, et al.
Publicado: (2022)

P06 Pharmacokinetics and renal accumulation of VRP-034
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022)

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
por: Sagan, Olexiy, et al.
Publicado: (2020)

In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii
por: Gill, Christian M, et al.
Publicado: (2023)

1042 Prevalence of Fluoroquinolone- and Ceftriaxone-resistant E. coli among U.S. Emergency Department Patients with Acute Pyelonephritis
por: Moran, Gregory, et al.
Publicado: (2014)

Emphysematous pyelonephritis
por: Yadav, Navin Kumar, et al.
Publicado: (2020)

Comparison in a rat thigh abscess model of imipenem, meropenem and cefoperazone-sulbactam against Acinetobacter baumannii strains in terms of bactericidal efficacy and resistance selection
por: Fetiye, Kolayli, et al.
Publicado: (2004)

Identification of Multiple Low-Level Resistance Determinants and Coselection of Motility Impairment upon Sub-MIC Ceftriaxone Exposure in Escherichia coli
por: Ching, Carly, et al.
Publicado: (2021)

P05 In vivo efficacy of VRP-034 in lung and thigh infection models
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022)

1228. Outcomes Associated with Empiric Cefepime or Meropenem for Bloodstream Infections Caused by Ceftriaxone-Resistant, Cefepime-Susceptible Escherichia coli and Klebsiella pneumoniae
por: Frescas, Brian E, et al.
Publicado: (2021)

Performance of the EUCAST disc diffusion method and two MIC methods in detection of Enterobacteriaceae with reduced susceptibility to meropenem: the NordicAST CPE study
por: Haldorsen, Bjørg, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_edmmvqo7o1ja9b7kgentf9m316